## Sympathetic Vasoconstriction Mechanism **Key Point:** Alpha-1 adrenergic receptors are the primary mediators of sympathetic-induced vasoconstriction in peripheral resistance vessels (arterioles and small arteries). ### Receptor Distribution and Function | Receptor Type | Location | Primary Effect | Clinical Relevance | |---|---|---|---| | Alpha-1 | Vascular smooth muscle (arterioles) | **Vasoconstriction** | Increases peripheral resistance and blood pressure | | Alpha-2 | Presynaptic terminals, some vascular beds | Inhibits norepinephrine release; mild vasoconstriction | Negative feedback; central sympathetic inhibition | | Beta-1 | Heart, juxtaglomerular cells | Increased HR, contractility, renin release | Cardiac effects dominate | | Beta-2 | Bronchi, skeletal muscle vessels | **Vasodilation** | Opposes alpha-1 effect | **High-Yield:** In the peripheral circulation, alpha-1 receptors outnumber alpha-2 receptors by approximately 10:1. This makes alpha-1 the dominant receptor for maintaining peripheral vascular tone and blood pressure regulation. ### Mechanism of Alpha-1–Mediated Vasoconstriction 1. Norepinephrine (or epinephrine at high concentrations) binds to alpha-1 receptors on vascular smooth muscle 2. Activates phospholipase C → IP₃ and DAG generation 3. IP₃ triggers Ca²⁺ release from sarcoplasmic reticulum 4. Increased intracellular Ca²⁺ → smooth muscle contraction 5. Net result: increased peripheral resistance and blood pressure **Clinical Pearl:** Alpha-1 antagonists (prazosin, doxazosin) are used to treat hypertension and benign prostatic hyperplasia because they selectively block this vasoconstriction pathway. **Mnemonic:** **ABCD of adrenergic effects** — Alpha-1 = Arteries (vasoconstriction), Beta-1 = Blood pressure (via heart), Beta-2 = Bronchi (dilation).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.